'That would be dreadful': The ethical, legal, and social challenges of sharing your Alzheimer's disease biomarker and genetic testing results with others.

"Lingler JH, Klunk WE. Disclosure of amyloid imaging results to research participants: Has the time come? ScienceDirect . Alzhiemer’s & Dementia . 9(6):741–744.e2 (2013). Wake T, Tabuchi H, Funaki K, Ito D, Yamagata B, Yoshizaki T, et al. Disclosure of amyloid status for risk of Alzheimer disease to cognitively normal research participants with subjective cognitive decline: A longitudinal study . American Journal of Alzheimer's Disease and Other Dementias 35:153331752090455 (2020)."

"FUNDING This research was supported by the Investigator-Initiated Research Grant ‘Study of Knowledge and Reactions to Amyloid Testing‘ awarded to Dr. Karlawish from the Alzheimer’s Association. It was also supported by grant P30AG010124 from the National Institute on Aging (Dr. Karlawish, co-investigator), and the Banner Alzheimer’s Institute WISP. Dr. Largent is supported by the National Institute on Aging (K01-AG064123) and a Greenwall Faculty Scholar Award. Dr. Stites is supported by the Alzheimer’s Association (AARF-17-528934) and the National Institute on Aging (K23AG065442). The funders had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation or approval of the manuscript; and decision to submit the manuscript for publication."

"Wilkins CH, Schindler SE, Morris JC. Addressing health disparities among minority populations: Why clinical trial recruitment is not enough . JAMA Neurology , 77(9):1063 (2020)."